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Introduction
Sphingolipids and their glycosylated derivatives, glycosphingolip-
ids (GSLs), are essential structural components of mammalian cell 
membranes and are characterized by heterogenic composition 
among tissues and even in the same cell during different states of 
development (1). Quantitative and qualitative changes of the cel-
lular GSL profile have long been recognized as a trait of malignant 
transformation (2). Surface-bound as well as shed GSLs have been 
shown to modulate cellular functions that promote tumor survival 
and growth, metastasis, and angiogenesis (2, 3).
In addition to conferring structural integrity to the cell mem-
brane, GSLs agglomerated into cholesterol dense microdomains or 
lipid rafts participate in cellular recognition, adhesion processes, 
and modulation of signal transduction events. Signaling through 
lipid raft–associated GSLs has been shown to be an important 
process in many cell types, including myeloid cells, lymphocytes, 
and osteoclasts (OCs) (4). For example, GM3 has been shown to 
regulate lipid raft–mediated cell signaling and cellular adhesion 
in human lymphocytes (5–7). Increased synthesis of GM3 is also 
a defining characteristic that marks the differentiation and mat-
uration of myeloid lineage precursors into monocytes and macro-
phages, a process that can be promoted by addition of GM3 (8).
OCs, the only cell type able to resorb bone, are also derived 
from myeloid precursors and form in response to stimulation 
with RANKL and M-CSF (9, 10). These cells play a crucial role 
in healthy bone homeostasis and are vital for the formation and 
maintenance of the BM hematopoietic stem cell (HSC) niche (11), 
as well as the regulation of hematopoiesis (12–14). The importance 
of OC activity in the HSC niche is best understood in various dis-
ease settings. BM modifications due to enhanced activation of 
OCs are involved in metastatic cancer (15, 16) and in multiple mye-
loma–related (MM-related) lytic bone lesions (17).
Previous in vitro studies suggest that de novo synthesized 
GSLs are required for OC development in vitro (18). Specifically, 
d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol 
(d-PDMP), a nonspecific inhibitor of glucose ceramide synthase 
(GCS) — an enzyme critical for GSL biosynthesis — prevents OC 
development (18). The role of GSL in OC biology is further high-
lighted by the development of OC activation–dependent crippling 
bone disease in lipid storage disorders (e.g., Gaucher disease) (19, 
20), which are caused by impaired catabolism of GSLs. Notably, 
N-butyl-deoxynojirimycin (NB-DNJ; also known as Miglustat), 
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after treatment with M-CSF and RANKL commenced and hence 
when mononuclear OCs had already formed. Mature OCs were 
identified by tartrate-resistant acid phosphatase (TRAP) activity 
as well as by phalloidin staining, reflecting F-actin polymerization 
and acquisition of resorptive activity. We found that d-PDMP, 
NB-DNJ, and N-OD-DNJ but not NB-DGJ effectively prevented 
the formation of mature OCs 2 days later (Figure 1, C and D). 
To determine the direct effect of iminosugar inhibitors on OC 
resorptive activity, we performed resorption pit assays on den-
tine. Inhibitors were added to murine BM cells 3 days after cul-
ture initiation with M-CSF and RANKL. After 14 days, d-PDMP, 
NB-DNJ and N-OD-DNJ but not NB-DGJ effectively reduced pit 
numbers and pit surface area as compared with untreated cul-
tures, consistent with inhibition of OC maturation and activation 
(Figure 1, E and F).
Knockdown of Ugcg inhibits OC formation. In order to test 
whether inhibition of GCS, and thus of the GSL biosynthesis 
pathway, by the iminosugar agents is responsible for the impaired 
osteoclastogenesis, we used two previously validated (33) shRNAs 
against UDP-glucose ceramide glucosyltransferase (Ugcg), i.e., the 
gene encoding GCS. First, using quantitative PCR (q-PCR) assay, 
we confirmed that as compared with scrambled control, sh783 
and sh875 effectively reduced Ugcg mRNA levels (Supplemental 
Figure 2A). As shown in Figure 2, RAW264.7 cells transfected with 
sh783 and sh875 generated significantly fewer (Figure 2E) and 
also smaller OCs (Figure 2F) than cells transfected with scram-
bled shRNA. Importantly, inhibition of osteoclastogenesis by Ugcg 
knockdown was not due to changes in cell viability, as shown by 
MTT assay (Supplemental Figure 2B).
NB-DNJ perturbs OC lipid raft organization and NFATc1 nuclear 
localization. The ganglioside GM1, also known as a glycosphingo-
lipid-enriched microdomain marker, is invariably associated with 
lipid rafts — cell membrane signaling platforms rich in GSLs — 
with a subset of lipid rafts defined by the presence of caveolin-1 
(34, 35). RANK, upon its engagement by its ligand RANKL, shifts 
into lipid rafts (4). RANK interacts with the raft-associated mol-
ecules TRAF6, an adaptor protein mediating activation of down-
stream signaling in developing OCs, including MAPK-dependent 
signaling; and c-SRC kinase, required for F-actin polymerization 
and OC resorptive activity (36). We tested whether disruption of 
GSL synthesis by NB-DNJ would perturb raft function and asso-
ciation of M-CSF receptor (M-CSFR), TRAF6, and c-SRC with the 
raft in response to RANKL.
As large numbers of OCs are required to obtain enough pro-
tein for this method, we used the murine macrophage cell line 
RAW264.7, which readily differentiates into OCs in response to 
RANKL (4, 37). First, we confirmed that OC formation was effec-
tively inhibited by NB-DNJ when these cells were used as OC 
precursors, similar to both the primary mouse and human OCs 
(Supplemental Figure 1C). Next, the cell lysate was separated over 
a discontinuous sucrose gradient by ultracentrifugation in 9 frac-
tions. Fractions 2–5 were enriched in lipid rafts, as indicated by the 
presence of GM1 (Figure 3A). In untreated RAW264.7 cells (Figure 
3A), M-CSFR was found to reside primarily in the non-raft part of 
the cell membrane, with only a small proportion associated with 
the rafts; likewise, TRAF6 was found almost exclusively outside 
the rafts, while as previously reported (4), a significant propor-
an iminosugar inhibitor of GCS, is taken up by glucocere-
broside-laden macrophages, thus ameliorating the clinical phe-
notype of Gaucher disease, as well as improving the osteoporotic 
bone phenotype (21, 22).
In MM, an incurable malignancy of plasma cells, osteolytic 
bone disease and skeletal complications occur in more than 80% 
of patients (23). Myelomatous osteolysis is localized to areas adja-
cent to tumor growth and is characterized by increased activity 
of OCs and suppression of osteoblastogenesis (23). Addition-
ally, OCs can promote myeloma cell survival and protect the 
malignant cells from spontaneous and drug-induced apoptosis 
(24). Increased secretion of RANKL from stromal cells is the 
prime mechanism of OC activation in MM (25–27). In addition, 
increased secretion of the chemokine macrophage inflammatory 
protein–1α (MIP-1α) (28–30) and cytokines such as IL-3 (1), VEGF 
(2, 3), and IGF-1 (4) in the myeloma microenvironment also con-
tribute to OC activation.
Whether myeloma-associated GSLs can modify the micro-
environment and in particular contribute to OC activation 
is not known. Through a series of in vitro and in vivo assays, 
we delineate the cellular and molecular mechanisms of OC 
development and function in the presence of exogenous GM3, 
which we identify as the prevailing GSL in myeloma cells, and 
upon endogenous GSL inhibition with the clinically approved 
iminosugar NB-DNJ. Our results suggest that NB-DNJ may be 
an effective agent for the treatment of malignant bone loss 
associated with increased OC activity in MM and may be appli-
cable to all cancer-induced bone diseases.
Results
Iminosugar agents inhibit RANKL-dependent OC development. Pre-
vious work showed that the nonspecific GCS inhibitor d-PDMP 
inhibited OC development, suggesting that endogenous GSL 
synthesis by OCs themselves is required for their development 
(18). To test the role of de novo GSL synthesis in OC development 
in vitro, M-CSF– and RANKL-dependent murine BM OC assays 
were performed in the presence of NB-DNJ, N-butyl-deoxyga-
lactonojirimycin (NB-DGJ), or N-octadecyl-deoxynojirimycin 
(N-OD-DNJ), three different iminosugar inhibitors of GCS, the 
enzyme that catalyzes the first and rate-limiting glycosylation 
step in GSL biosynthesis (31). Using a dose range that had pre-
viously been shown to inhibit glycolipid biosynthesis (32), we 
found that after 5 days of culture, d-PDMP, NB-DNJ, NB-DGJ, 
and N-OD-DNJ inhibited OC formation in a dose-dependent 
manner (Figure 1, A and B), without affecting cell viability (Sup-
plemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI59987DS1). d-PDMP, NB-DNJ, 
and N-OD-DNJ almost completely inhibited OC development at 
the higher concentration of 500 μM, but NB-DGJ was less effec-
tive. A similar inhibitory effect was observed on human elutri-
ated monocytes induced to form OC in vitro with increasing 
doses of NB-DNJ, thus confirming a direct effect of iminosugar 
agents on OC precursors and the involvement of de novo GSL 
production in OC formation (Supplemental Figure 1B).
To assess whether the iminosugar inhibitors would affect 
the process of OC fusion that is required for the development of 
mature OCs, we added these compounds into OC cultures 3 days 
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Figure 1. GSL inhibitors inhibit osteoclastogenesis and bone resorption in vitro. (A) Mouse BM cells were cultured in the presence of 25 ng/ml M-CSF 
with 50 ng/ml RANKL (Control) and with or without d-PDMP (5, 20, or 50 µM), NB-DNJ, NB-DGJ, or N-OD-DNJ (5, 50, or 500 µM) in 48-well plates for 
5 days, and TRAP-positive OCs were counted and shown as cumulative results from 3 different experiments. (B) Cultures with iminosugar inhibitors 
at 500 µM and d-PDMP at 20 µM were photographed (original magnification, ×40). (C and D) Mouse BM cells were cultured with 25 ng/ml M-CSF and 
50 ng/ml RANKL in 48-well plates. On day 3 d-PDMP (20 µM) or NB-DNJ, NB-DGJ, or N-OD-DNJ (each at 500 µM) was added. Cells were cultured for 
another 48 hours before being fixed and stained for TRAP and counted (C) and phalloidin stained to identify mature OCs by the formation of actin rings 
(D) (original magnification, ×40). (E and F) Mouse BM cells cultured with M-CSF and RANKL on dentine slices with 5 µM d-PDMP or 50 µM iminosugars 
added on day 1 were evaluated on day 14 when resorption lacunae on dentine slices were visualized with methylene blue (original magnification, ×4). 
(F) Resorption area is expressed as a percentage of the dentine surface area. A representative experiment of three, each performed in triplicate assays, 
is shown for C and F. Data are mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test 
(*P < 0.05, **P < 0.01, ***P < 0.001 versus control).
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of primary myeloma cells from four patients and human MM cell 
lines by mass spectrometry (42). As shown in Table 1 and Figure 4, 
A and B, MALDI-TOF mass spectra of GSLs showed that GM3 was 
the most abundant GSL in primary myeloma CD138+ tumor cells 
(n = 1; the cluster of molecular ion peaks between m/z 1,372 and 
1,482), as well as in all of the human MM cell lines tested. GM2 was 
also abundant in MM cell lines but not in primary myeloma cells. 
Neither GM3 nor GM2 was present in myeloma patient–derived, 
CD138– non-malignant BM cells (n = 3); instead, lactosylceramide 
(m/z 1,011) and GA1 (cluster of molecular ion peaks between m/z 
1,460 and 1,570) were the predominant GSLs in these cells. The 
preponderance of lactosylceramide over GM3 and GM2 was also 
observed in bone marrow samples from healthy donors, as deter-
mined by HPLC (Supplemental Table 1). Finally, analysis of puri-
fied malignant CD138+ plasma cells by HPLC confirmed GM3 as 
one of the most abundant polar GSLs in 4 of 6 patients and GM2 in 
1 of 6 patients (Figure 4C). Thus, GM3 and GM2 were the predom-
inant GSL constituents of patient myeloma cells and MM cell lines 
(43) (Figure 4 and Table 1).
GM3 cooperates with RANKL and IGF-1 to promote OC matu-
ration. Given its abundance in myeloma cells, we next tested the 
hypothesis that exogenous GM3 can modify the BM environment 
and specifically contribute to OC activation in a paracrine fashion. 
For this purpose, murine BM OCs were generated in the presence of 
conventional M-CSF concentration (25 ng/ml) but a limiting con-
centration of RANKL (5 ng/ml); multinucleated (≥3 nuclei) OCs 
were enumerated after TRAP staining. In this system, the addition 
of GM3 to RANKL and M-CSF further enhanced the formation 
of mature OCs in a dose-dependent manner by day 7 (Figure 5A). 
tion of c-SRC resided in the rafts. Upon RANKL treatment (Figure 
3A), a clear shift of M-CSFR, TRAF6, and caveolin-1 into the raft 
fraction was observed, with almost all c-SRC localized in the rafts. 
In the presence of NB-DNJ (Figure 3A), RANKL-induced move-
ment of TRAF6 and M-CSFR into rafts was not observed, while 
c-SRC and caveolin-1 only existed outside the raft fraction. Taken 
together, these findings show that iminosugar inhibitors perturb 
association of molecules critical for OC differentiation and activa-
tion with lipid rafts.
Next we investigated the effect of NB-DNJ on OC signaling. 
In response to RANKL, signaling occurs via the MAPK and NF-κB 
pathways, leading to the activation of OC-specific genes via the 
binding of transcription factors such as NFATc1 and AP1 (38, 
39). When we investigated MAPK signaling in RAW264.7 cells in 
response to RANKL or M-CSF treatment, there was the expected 
upregulation of the three MAPK pathways; however, there was no 
significant change in the phosphorylation of p38, ERK, or JNK fol-
lowing NB-DNJ treatment (Supplemental Figure 3, A and B). One 
of the key transcription factors in osteoclastogenesis is NFATc1, 
which is induced via TRAF6/NF-κB and c-Fos pathways and 
autoamplifies to give robust activation of OC-specific genes such 
as TRAP and cathepsin K (38, 40, 41). Using immunofluorescence 
microscopy, we observed nuclear localization and accumulation of 
NFATc1 in response to RANKL treatment; the addition of NB-DNJ 
prevented this nuclear accumulation of NFATc1 (Figure 3B).
GM3 and GM2 are the dominant polar GSLs in MM cells. As a 
first step in investigating the potential role of myeloma-derived 
GSL in modifying the tumor microenvironment and specifically 
contributing to OC activation, we determined the GSL profiles 
Figure 2. Knockdown of Ugcg inhibits OC formation. OCs derived from non-transfected, PBS-treated (A) and transfected RAW264.7 cells (B–D) were 
TRAP stained and imaged using an Olympus inverted microscope with ×10 magnification. RAW264.7 cells were transfected with scrambled shRNA 
(shScr) (B) or with sh783 (C) or sh875 shRNA (D). OC count at ×10 fields from 2 different experiments, with each experiment performed in triplicate, 
was used to generate individual plots (E), and the mean size of OCs is expressed in pixels (F). Statistical differences in TRAP-positive cells (E) were 
analyzed with standard one-way ANOVA, and differences in mean size (F) were analyzed with the Kruskal-Wallis ANOVA test. Error bars correspond to 
SEM. n = 6; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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cooperate with both RANKL and IGF-1 to pro-
mote OC maturation.
GM3-mediated OC activation and effect of 
NB-DNJ in vivo. Next we tested whether GM3 
would promote OC development and activa-
tion in vivo and the effect of NB-DNJ on this 
process. To determine the optimal in vivo 
dose of NB-DNJ, we treated five groups of 
mice with 0–100 mg/mouse/d of inhibitor for 
6 days by oral gavage. The overall biological 
activity of NB-DNJ was assessed by HPLC in 
a surrogate assay that tracks the levels of free 
plasma glucose–containing oligosaccharides 
(45). These are generated as a result of inhibi-
tion of ER-resident α-glucosidases I and II by 
NB-DNJ, leading to glycoprotein misfolding 
and eventually — as misfolded proteins are 
degraded in the proteasome — release of free 
oligosaccharides (45). We found that detec-
tion of plasma oligosaccharides was dose 
dependent and highest at the largest dose 
used (100 mg/mouse/d), corresponding to a 
serum level of NB-DNJ of 109.3 ± 5.3 μM (Fig-
ure 6A). Analysis of BM cells also confirmed 
GSL depletion in a dose-dependent manner 
(Figure 6B). Furthermore, in vitro assays 
using BM from mice treated for 6 days with NB-DNJ showed a 
dose-dependent reduction in OC numbers at a dose of 75–100 
mg/mouse/d, resulting in an approximately 30% reduction as 
compared with PBS-treated controls (Figure 6, C and D), sug-
gesting that NB-DNJ has an anti-osteoclastogenic effect in vivo.
To address whether GM3 exerts a pro-osteoclastogenic effect 
in vivo and how such an effect might be modified by NB-DNJ, we 
studied ex vivo OC formation and activity using BM cells from 
mice treated with PBS, GM3+PBS, NB-DNJ, or GM3+NB-DNJ. In 
line with the in vitro results, assessment on day 7 of the experi-
ment when the mice were sacrificed showed that as compared 
with PBS treatment, a single injection of GM3 on day 4 resulted 
in a significant increase in the number of in vitro generated OCs. 
However, in mice treated with NB-DNJ, the enhanced osteoclas-
togenesis observed after GM3 injection was abrogated (Figure 
7A). Furthermore, OCs from mice treated with GM3 displayed 
greater resorptive activity in ex vivo pit assays than OCs from PBS-
treated mice, and again this effect was reversed in mice receiving 
GM3+NB-DNJ (Figure 7B).
Cells cultured with GM3 and M-CSF in the absence of RANKL did 
not form OCs (data not shown). The pro-osteoclastogenic effect of 
GM3 was also observed in human OC assays, in which elutriated 
PBMCs were differentiated into OCs in the presence of M-CSF and 
a suboptimal concentration of RANKL (Supplemental Figure 4); 
this demonstrated a direct effect of GM3 on OCs, as there are no 
contaminating stromal cells present in the human cell preparation. 
Taken together, these results show that the pro-osteoclastogenic 
effect of GM3 occurs via direct action on OC precursors under per-
missive conditions, i.e., in the presence of a source of RANKL.
Since previous work in Igf1–/– mice suggested that IGF-1 is a 
pro-osteoclastogenic factor and it plays a significant role in the 
biology of MM (44), we tested whether GM3, as well as RANKL, 
could also cooperate with IGF-1 to promote osteoclastogenesis. 
First, in line with a direct pro-osteoclastogenic effect, we found 
that IGF-1 in the presence of a limiting concentration of RANKL 
enhanced murine OC formation in a dose-dependent manner 
(Figure 5B), while GM3 and IGF-1 in combination with RANKL 
additively enhanced OC maturation (Figure 5C). Thus, GM3 can 
Figure 3. GSL inhibitors perturb the association of 
SRC and TRAF6 with lipid rafts during osteoclasto-
genesis. (A) Localization of M-CSFR, TRAF6, c-SRC, 
and GM1 ganglioside in the lipid raft (fractions 3–5) 
or non-raft fractions (fractions 7–9) in RAW 264.7 
cells cultured in medium only (control) or in the 
presence of 50 ng/ml RANKL or RANKL+NB-DNJ in 
48-well plates for 4 days. Representative blots from 
3 separate experiments are shown. (B) Overnight 
serum-starved OCs stained with anti-NFATc1 and 
anti-mouse–Alexa Fluor 546 and viewed by immuno-
fluorescence microscopy.
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Analysis of in situ OC development on histological bone sec-
tions stained for TRAP (Figure 7C) showed a significantly higher 
number of OCs (Figure 7D), with increased surface area (Figure 
7E) in mice treated with GM3 plus PBS, an effect that was almost 
entirely reversed in GM3+NB-DNJ–treated mice. In vivo resorp-
tive OC activity as assessed by serum C-terminal telopeptides of 
collagen type I (CTX) levels also showed a significant increase 
in response to GM3 and reversal of this effect in GM3+NB-DNJ–
treated mice (Figure 7F). Finally, the same inhibitory effect of 
NB-DNJ as assessed by serum CTX levels was observed when 
osteoclastogenesis was activated by α-galactosylceramide, a gly-
colipid that, as we previously demonstrated, promotes differen-
tiation and maturation of OCs in vivo (46) (Supplemental Figure 
5). Therefore, in line with the in vitro studies, exogenous GM3 
exerted significant pro-osteoclastogenic activity in vivo, while 
treatment of mice with NB-DNJ effectively inhibited baseline as 
well as GM3-induced OC development and function.
NB-DNJ effectively reduces osteolytic bone lesions in the 5TGM1 
murine myeloma model. To assess the effectiveness of NB-DNJ 
on MM disease progression, we employed the murine myeloma 
5TGM1 model (47, 48). First we determined that in vitro, NB-DNJ 
had a modest inhibitory effect (up to 25%) on the viability of 
5GTM1-GFP cells (Supplemental Figure 6A) and that as in human 
myeloma cells, GM3 was the most abundant GSL (64.8% ± 1.2%; 
n = 3) in 5GTM1-GFP cells. Next, C57BL/KaLwRijHsd mice 
receiving transplants of 5GTM1-GFP cells were treated with PBS 
(n = 6) or NB-DNJ (50 mg/d, n = 6) starting day 4 after transplant. 
Non-transplanted and PBS-treated mice (n = 6) served as naive 
controls. On day 26 all of the mice were killed, and the tumor 
burden was assessed via GFP expression by flow cytometry. In 
both the BM and spleen, NB-DNJ treatment reduced the percent-
ages of 5TGM1-GFP cells by 30%–40% when compared with the 
PBS-treated groups; however, this was not statistically significant 
(Supplemental Figure 6B).
To determine the consequences of GSL inhibition on OC 
activity in a pathologic setting, we performed histomorphometric 
evaluation of TRAP-stained longitudinal cross sections of tibiae. 
MM-diseased and PBS-treated mouse tibiae showed a signifi-
cantly higher number of OCs with increased surface area when 
compared with naive control mice (Figure 8A). However, NB-DNJ 
treatment of MM-diseased mice reduced OC number and sur-
face area (Figure 8A). Further, tibiae were evaluated for osteo-
lytic bone lesions by micro-CT analysis. Treatment with NB-DNJ 
decreased bone loss in vivo and reduced myeloma-induced lytic 
bone lesions, as shown by a significant increase in bone param-
eters such as bone volume (BV/TV) and trabecular thickness 
(Tb.Th), and a consequent decrease in trabecular pattern factor 
(Tb.Pf) (Figure 8, B and C, and Supplemental Figure 7). All bone 
parameters from myeloma diseased and NB-DNJ–treated mice 
were either similar (bone surface density [BS/BV], number of tra-
beculae [Tb.N], Tb.Pf, structure model index [SMI]) or close (BV/
TV, Tb.Th) to the values in the naive control animals, as shown in 
Figure 8C. Taken together, these findings are consistent with the 
in vitro results, i.e., that NB-DNJ could inhibit the function of OCs 
activated by either exogenous GSLs such as GM3 or by de novo 
synthesized, endogenous GSLs.
Discussion
We demonstrate here that GSLs, and in particular GM3, play an 
important role in OC activation. We have further shown by mass 
spectrometry and HPLC analysis that GM3 is the dominant polar 
GSL present in myeloma cells. Importantly, the administration of 
the GSL inhibitor NB-DNJ was able to reduce osteolytic lesions in a 
mouse model of MM (47). In vitro, GM3 promoted osteoclastogen-
esis in the presence of a limiting RANKL concentration in a cooper-
ative manner. This was demonstrated by culturing BM or elutriated 
PBMCs with a suboptimal dose of RANKL; this allows for the mea-
surement of further OC differentiation following GM3 addition.
It is not yet clear how exogenous GM3 enhances the effect of 
RANKL and M-CSF in vitro. It was previously shown that GSLs 
can directly incorporate into the cell membrane, and through 
lateral interaction with signaling proteins such as the EGF and 
VEGF receptors, it can modulate downstream signaling (49). It 
is possible that in an analogous way, exogenous GM3, by incor-
porating into the cell membrane of developing OCs, can increase 
the responsiveness of RANK and M-CSFR to their ligands, 
RANKL and M-CSF, respectively. In support of such mechanism, 
stromal cell–derived GM3 was previously shown to incorporate 
into the cell membrane rafts of the myeloid cell progenitor line 
FDCP1 and, through interaction with GM-CSF receptor, to pro-
Table 1. Mass spectrometry profiling of glycan moiety of GSLs from patient BM cells and human myeloma cells lines
GSL CD138+, Pat A CD138–, Pat B CD138–, Pat C CD138–, Pat D KMS11 KMS12 RPMI8226 U266 JJ3N
Lactosyl 2, 4 98, 100 100, 100 100, 100 1, 3 9, 2 20, 0
Hex3 34, 5
HexHexNAcHex2 100, 78 59, 44 49, 58 26, 5 <1, 0
GM3 100, 100 0, 6 8, 11 5, 5 2, 22 100, 56 17, 15 100, 100
GM2 100, 100 100, 100 60, 100 100, 100 90, 67
GM1a 5, 3 37, 41 23, 34 12, 24 1, <1 4, 4
NeuAc2LacNAc2Hex2 3, 2 <1, <1 6, 2
Values represent the glycan moiety of the GSLs as % relative intensity. For each GSL, the first value corresponds to the 80% and the second value to the 
100% propanol fraction from a C18 Sep-Pak (Waters; ref. 42) (see Methods). %Relative intensity was calculated as follows: All spectra were subjected to 
peak deisotoping. The percent relative intensity of all GSLs that corresponded to the same glycan moiety with all possible ceramide moieties were summed 
up. The summed up percent relative intensities of all GSLs in the same spectrum were normalized (100%) to the maximum relative intensity. Empty cells 
indicate that GSLs were under the detection limit. Pat, patient.
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Figure 4. GSL profiles of primary human myeloma cells and human MM cell lines. (A and B) MALDI-TOF mass spectra of permethylated GSLs from 
human primary cells. Upper-phase GSLs from (A) MM patient CD138+ and (B) MM patient CD138– BM cells. Profiles of GSLs are from the 80% (left panels) 
and 100% propanol (right panels) fractions from a C18 Sep-Pak (Waters; ref. 42). The inset corresponds to a zoomed scan of the GM3 cluster area. GSLs are 
indicated as cartoon structures for the glycan moiety and composition of the fatty acid for the lipoform moiety, with d-erythro-sphingosine considered as 
the sphingosine base. Cartoon structures are according to Consortium for Functional Glycomics (http://www.functionalglycomics.org) guidelines. Fatty 
acid composition is indicated below each cartoon structure. Unassigned peaks correspond to chemical derivatization artifacts and/or to structures not 
corresponding to GSLs. All molecular ions are [M+Na]+. Structural assignments of the glycan moieties are based on monosaccharide composition, tandem 
mass spectrometry, and known biosynthetic pathways. (C) HPLC analysis of CD138+ selected plasma cells from 6 patients with MM. In 4 of 6 cases, GM3 is 
the predominant GSL, followed by GM2. Absolute quantification of GM3 is also shown. The top panel shows the various marker GSLs used for identifica-
tion. GalNAc, N-acetylgalactosamine; HexNAc, N-acetylhexoseamine; NeuAc, N-acetylneuraminic acid.
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The in vitro effects of GM3 as a pro-osteoclastogenic factor 
were supported by its effects in vivo. GM3 significantly promoted 
OC development and function, as shown by increased OC num-
bers and surface in situ and serum CTX levels, and both of these 
effects were effectively inhibited by NB-DNJ. Exogenous GM3 has 
been shown previously to incorporate into cell membranes and 
lipid rafts of myeloid cells and to promote downstream cell signal-
ing (50, 51). It is possible, therefore, that disruption of lipid rafts 
in OC precursors by NB-DNJ prevents the OC-activating effect of 
exogenous GM3.
Increased GSL biosynthesis (59, 60) and GSL-mediated pro-
motion of angiogenesis and metastatic tumor growth (6) have 
been demonstrated in different types of cancers. We have shown 
that GM3 is the predominant polar GSL produced by both mye-
loma cell lines and primary myeloma cells from patients with 
MM. Furthermore, the administration of NB-DNJ to mice sus-
ceptible to developing MM following transplantation of 5TGM1 
myeloma cells demonstrated the effectiveness of this GSL inhib-
itor in limiting osteolytic bone lesion development. Although the 
reduction in myeloma cell burden of 30%–40% did not reach 
statistical significance, our data suggest direct antimyeloma 
activity of NB-DNJ. Hence, it seems likely that the combination 
of reduced myeloma cell burden along with substantial inhibi-
tory effects of NB-DNJ on OCs prevents the development of 
osteolytic bone lesions. It is possible that the well-established 
murine 5TGM1 MM model with its short duration of only 26 days 
does not reveal NB-DNJ’s full effects on myeloma cell burden; 
however, our in vitro data confirm an NB-DNJ inhibitory effect 
on 5TGM1 cells.
Taken together, our in vitro and in vivo data suggest that this sal-
utary effect of NB-DNJ on myeloma-induced bone disease is multi-
factorial and the result of reduced pro-osteoclastogenic GM3 pro-
duction by the tumor cells, as well as inhibition of OC development 
and maturation through inhibition of de novo GSL synthesis. There-
fore, since nearly all MM patients experience the consequences of 
MM-related bone disease, we propose that the clinically approved 
NB-DNJ and possibly other GCS inhibitors can be used as clinical 
agents to abrogate pathological OC activation in MM.
In summary, we showed here that GM3, the main GSL con-
stituent of myeloma plasma cells, is a pro-osteoclastogenic factor 
in vitro as well as in vivo. The inhibitory effect of NB-DNJ on de 
mote cell proliferation in response to GM-CSF (50, 51). Alterna-
tively, exogenous GM3 might act indirectly by promoting secre-
tion of pro-osteoclastogenic factors from other BM cells, such as 
osteoblasts, monocytes/macrophages, and T cells. However, the 
pro-osteoclastogenic effect of GM3 in our ex vivo experiments 
supports a direct role for GM3 and GSL on OC precursor differen-
tiation, as GM3 participates in RANKL-induced osteoclastogen-
esis, and reduced OC fusion and activation are observed in the 
absence of GSL biosynthesis. Although not directly tested, it is 
likely that GM2, another prominent GSL in some myeloma cells, 
exerts a similar direct pre-osteoclastogenic effect.
We show inhibition of OC development and maturation by 
pharmacological and genetic inhibition of Ugcg, the gene encoding 
for GCS, the rate-limiting enzyme in GSL synthesis. This suggests 
an important role for de novo synthesized GSL in baseline osteo-
clastogenesis. Among the iminosugar inhibitors tested, NB-DNJ 
has been therapeutically successful in patients with lysosomal 
storage diseases by reducing the overall burden of unprocessed 
GSLs through inhibition of de novo synthesis of GSLs (31, 52). In 
these patients, increased OC activation and osteoporosis occur as 
a consequence of the lysosomal storage disease, and treatment 
with NB-DNJ results in a significant restoration of bone mass (22).
We identify lipid rafts as an important target for the biological 
effect of NB-DNJ (53). These GSL-rich membrane structures are 
required for the clustering of growth factor receptors, including 
RANK (4) and IGF1R (54), and subsequent activation of down-
stream signaling, including the MAPK-dependent pathways (55). 
We show that the reduced presence of GM1 in the rafts in response 
to NB-DNJ is associated with a significant reduction in raft-resident 
TRAF6 and c-SRC. TRAF6 is a pivotal adaptor that upon RANKL 
ligation binds to RANK and promotes OC differentiation as well as 
maturation (56, 57), while the presence of c-SRC in rafts is required 
for its association with β3 integrin and subsequent Rho GTPase–
dependent polymerization of F-actin (58). Mechanistically, by 
using NB-DNJ, we were able to show that GSLs are essential for 
clustering of TRAF6 in lipid rafts during RANKL signaling in OCs. 
Furthermore, the presence of NB-DNJ prevented the accumulation 
of NFATc1 in the nucleus. This transcription factor is essential for 
the expression of osteoclastogenic genes, and in its absence OC 
formation and activity would be impaired (40, 41), thus describing 
one of the consequences of NB-DNJ administration.
Figure 5. GM3 cooperates with RANKL and IGF-I 
to promote osteoclastogenesis. (A) Mouse BM 
cells were cultured in the presence of 25 ng/ml 
M-CSF and only 5 ng/ml RANKL (control) and GM3 
(0.05, 0.5, or 5 μM), (B) with IGF-1 (25, 50, or 100 
ng/ml), or (C) with IGF-1+ GM3 in the presence of 
RANKL and M-CSF in 96-well plates for 7 days, and 
OC numbers were evaluated by TRAP staining. A 
representative experiment of 3, each performed 
in triplicate assays, is shown (n = 3). Error bars 
correspond to SEM. Statistical analysis was per-
formed using one-way ANOVA followed by Tukey’s 
multiple comparisons test (*P < 0.05, **P < 0.01, 
***P < 0.001 versus control).
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Therapeutics, and NB-DGJ was purchased from Toronto Research 
Chemicals Inc. They were dissolved in water at 100 mM and stored at 
–20°C until use. For each experiment, they were diluted immediately 
before use in culture medium (5–500 μM).
In vivo assays. For in vivo experiments 8- to 10-week-old 
female WT C57BL/6 mice (Charles River) and 10-week-old female 
C57BL/KaLwRijHsd mice (Harlan) were maintained in the Biolog-
ical Services Unit, Kennedy Institute of Rheumatology, University 
novo and exogenous GM3-mediated OC activation and its ability 
to limit myeloma-induced bone loss in an animal model of dis-
ease provides a rational basis for a clinical study aiming at reduc-
ing OC activation and bone destruction in patients with MM.
Methods
GSL inhibitors. d-PDMP was purchased from Matreya LLC, NB-DNJ 
was provided by Sigma-Aldrich, N-OD-DNJ was a gift from United 
Figure 6. NB-DNJ inhibits ex vivo osteoclastogenesis in a dose-dependent manner. (A) Quantification of free serum oligosaccharides recovered by HPLC 
from NB-DNJ–treated mice. (B) GSL analysis of BM cells following administration of 0, 25, 50, 75, and 100 mg NB-DNJ. The representative species of 
oligosaccharides — GM1b, GA1, and GD2 — were identified in the BM of NB-DNJ–treated mice. (C) BM cells obtained from mice treated with different doses 
of NB-DNJ were induced to form OCs (with 25 ng/ml M-CSF and RANKL) in 96-well plates and were identified by TRAP staining (original magnification, 
×20). (D) Enumeration of TRAP-positive multinucleated cells/well differentiated from NB-DNJ–treated mouse BM (n = 5 mice/treatment; BM from each 
mouse was evaluated in triplicate). Error bars correspond to SEM (*P < 0.05, **P < 0.01, ***P < 0.001, versus 0 mg NB-DNJ); x axis represents NB-DNJ 
dose in mg/mouse/d in A, B and D. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test.
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volume of 200 μl. α-Galactosylceramide (a gift from S. Gadola, Uni-
versity of Southampton, Southampton, UK) or PBS was administered 
by a single i.p. injection of 2 μg on day 3. Serum was collected on day 
7, by intracardiac puncture. Bones were either fixed for histology or 
of Oxford. Animals were administered PBS or 0–5,000 mg/kg/d 
NB-DNJ (diluted in water) once a day by gavage in a volume of 200 
μl for 6 days (n = 5 mice/group). On day 4, PBS or 10 μg/mouse of 
GM3 (Sigma-Aldrich or Avanti Polar Lipids Inc.) was injected i.v. in a 
Figure 7. NB-DNJ inhibits GM3-mediated enhanced OC development and activity in vivo. (A) TRAP staining analysis of mouse OCs from different groups 
treated with GM3 and/or NB-DNJ as indicated in Methods after 7 days of culture. (B) Representative images of OC resorption pits on dentine (original mag-
nification, ×10). (C) Representative histological sections of mouse tibiae stained for OC TRAP activity and counterstained with 0.25% methyl green solution 
(original magnification, ×40). For A, B, and C, a representative experiment of 3 is shown, with n = 5 mice in each treatment group and with each individual BM 
sample evaluated in triplicate. (D and E) Bone histomorphometry parameters obtained by analyzing cumulatively the histological sections of two different 
experiments of 3 (n = 10). Number of OCs/total bone area (N.Oc/T.Ar); OC surface is expressed as percentage of total bone surface (Oc.S/BS). (F) Serum values 
of CTX (ng/ml) combined from two different experiments of 3 (n = 10). Error bars correspond to SEM. Statistical analysis was performed using one-way ANOVA 
followed by Tukey’s multiple comparisons test (*P < 0.05, **P < 0.01, ***P < 0.001 versus control).
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anthranilic acid. Following sep-
aration of labeled GSL-derived 
oligosaccharides by normal-phase 
HPLC, peak areas were measured 
using Empower software (Waters), 
converted to molar amounts using 
an experimentally derived fac-
tor, and normalized to cellular 
protein. Levels of serum NB-DNJ 
were determined as previously 
published (62).
In vitro OC formation and 
TRAP assay. Cells obtained from 
the BM of 8- to 10-week-old 
C57BL/6 mice were cultured 
at 37°C in 5% CO2 in complete 
medium — α-MEM with 10% FBS, 
100 U/ml penicillin, and 100 μg/ml 
streptomycin (Invitrogen) at a density of 5 × 105 cells/well in 96-well 
or 48-well plastic plates — and OC precursors were induced to pro-
liferate and differentiate with 20–25 ng/ml murine M-CSF (Pepro-
tech) and 5–50 ng/ml RANKL (PeproTech or R&D Systems) supple-
ments as indicated. Medium was changed every 3 days, and after 5 
or 7 days cells were washed with PBS and fixed with 4% paraform-
aldehyde, then permeabilized with acetone/ethanol 1:1 solution and 
stained for TRAP activity for 15 minutes at 37°C (0.1 mg/ml Naph-
thol AS-MX phosphate, 0.4 mg/ml Fast Red Violet LB Salt, 0.5 ml 
dimethylformamide in 50 ml TRAP buffer; all from Sigma-Aldrich). 
Multinucleated (≥3 nuclei) TRAP-positive cells were considered 
to be OCs. In all the experiments, BM cells were also cultured in 
flushed to obtain live BM cells. In order to establish the 5TGM1 mouse 
myeloma model (48), C57BL/KaLwRij mice were i.v. transplanted 
with 106 5TGM1-GFP cells (gift from Claire Edwards, University of 
Oxford, and Kay Oyajobi, University of Texas, San Antonio, Texas) 
in 100 μl PBS in the tail vein. Non-transplanted mice served as naive 
controls (n = 6 mice/group). Starting from day 4 after transplanta-
tion, mice were gavaged daily with PBS or NB-DNJ (2,500 mg/kg/d) 
for another 21 days.
HPLC profiling of GSL and free plasma glucose–containing oligo-
saccharide assay. As previously described (61), GSLs were extracted 
from cells and the oligosaccharide moiety removed using cera-
mide glycanase purified from Hirudo medicinalis and labeled with 
Figure 8. NB-DNJ effectively inhib-
its 5TGM1 myeloma cell–caused 
bone lesions in C57BL/KaLwRijHsd 
mice. (A) Representative histologi-
cal sections of TRAP-stained naive 
control (Ctr), myeloma-diseased and 
PBS-treated, or myeloma-diseased 
and NB-DNJ–treated (2,500 mg/kg/d) 
mouse tibiae (original magnification, 
×20) and tibial histomorphometric 
evaluation: number of OCs reported 
to total area (N.Oc/T.Ar)  
and OC surface reported to bone 
surface (Oc.S/BS). (B) Longitudinal 
cross section of diseased and PBS- 
or NB-DNJ–treated (2,500 mg/kg/d) 
mouse tibiae evaluated by micro-CT 
reconstruction. (C) Micro-CT analysis 
parameters of tibiae: BV/TV, BS/
BV, Tb.Th, bone surface (BS), Tb.N, 
Tb.Pf, SMI, and fractal dimension 
(FD). n = 6 mice/treatment;  
*P < 0.05, **P < 0.01, ***P < 0.001 
versus 5GTM1 cell–transplanted and 
PBS-treated mice; #P < 0.05 versus 
non-transplanted naive controls. 
Error bars correspond to SEM. Statis-
tical analysis was performed using 
one-way ANOVA followed by Tukey’s 
multiple comparisons test.
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10% EDTA for 21 days. To ensure proper decalcification, every 3–4 
days the EDTA solution was changed. After paraffin embedding fol-
lowing standard techniques, the bones were sectioned with a Sakura 
Accu-Cut SRM 200 microtome. Sections (4 μm) were stained for 
TRAP activity and counterstained with methyl green following stan-
dard procedures. Slides were analyzed using an Olympus Bx51 micro-
scope, and pictures were taken with an Olympus DP71 camera.
Bone histomorphometric analysis. Analysis of bone volume and 
bone surface and determination of OC numbers and OC surface 
were carried out using the OsteoMeasure histomorphometry system 
(OsteoMetrics) in accordance with American Society for Bone and 
Mineral Research (ASBMR) standard nomenclature (http://www.
asbmr.org/standardizationofbonestructureanddensitynomencla-
ture.aspx) on TRAP-stained and 0.25% methyl green counterstained 
4-μm-thick histological sections, as previously described (64, 65).
Micro-CT analysis. Mouse tibiae were harvested 26 days after 
5TGM1-eGFP myeloma cell transplant and fixed in 70% ethanol. 
Bones were scanned with a SkyScan 1174 scanner: 50 kV, 800 μA, 
8.3-μm isometric voxel resolution, 0.7-degree rotation step. Images 
were analyzed using SkyScan CT Analyzer software version 1.9.3.0. by 
selecting the trabecular region volume of interest commencing imme-
diately after the growth plate and preceding distally for 208 slices (1.72 
mm). A threshold of 80 density units was selected to distinguish min-
eralized from nonmineralized tissue.
Supplemental methods. Reagents and cell lines, Western blots, 
lipid raft isolation, phalloidin staining, ELISA, elutriation, cell viabil-
ity assays, and FACS analysis for myeloma burden are described in 
Supplemental Methods.
Statistics. One-way ANOVA was used for statistical analysis 
of all the experiments with more than three experimental groups, 
and a Tukey post hoc test, as described in the figure legends, was 
applied to determine the differences between the specific experi-
mental groups. For comparing only two experimental groups, we 
used two-tailed t tests. In all cases, data are presented as mean 
± SEM, and a P value of 0.05 was considered significant. For the 
statistical analysis of free oligosaccharides recovered by HPLC 
from mice serum, second-order polynomial regression was used.
Study approval. Animal care and experimental procedures were 
approved by the University of Oxford Local Ethical Review Commit-
tee under PPL 7161 and were conducted in accordance with the UK 
Home Office Animals Act of 1986. BM from myeloma patients was 
obtained after receipt of informed consent in accordance with the 
Declaration of Helsinki and the study was approved by Hammersmith 
Hospital NHS Trust Research Ethics Committee, London.
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complete medium with M-CSF but no RANKL, serving as a negative 
control for OC formation.
In vitro OC resorption assay. Resorptive activity of OCs was 
determined by a lacunar resorption assay on dentine disks placed in 
96-well plates according to regular techniques. Cells were cultured in 
complete medium as in the TRAP assay on dentine for 14 days with 
media changes every 3 days. Dentine disks were rinsed in dH2O to 
lyse and remove the OCs. Resorption pits were stained with toluidine 
blue or marked with carbon, and resorption areas were analyzed by 
using ImageJ software (http://imagej.nih.gov/ij/) and expressed as 
the percentage of resorption area per dentine.
RAW264.7 cell transfection with shRNA against mouse Ugcg. 
shRNAs targeting mouse Ugcg (sh783, 5′-CTCAGTACATTGCT-
GAAGATT, and sh875, 5′-TCTGGTTCGTACTCAATTTCT) were 
prepared as previously described (33). RAW264.7 cells were trans-
fected with scrambled shRNA, sh783, and sh875 using FuGENE HD 
(E2311, Promega). Seventy-two hours after transfection, GFP-pos-
itive cells were sorted and plated at a density of 0.1 × 105 cells per 
well in 24-well plates. OC differentiation was induced on both non
-transfected RAW264.7 and sorted transfected RAW264.7 cells, 
using 50 ng/ml M-CSF plus 75 ng/ml RANKL. After 7 days, cells 
were fixed and TRAP stained. TRAP-positive cells were counted, 
and the size of the OCs was measured using Fiji image analysis 
software (63). Data analysis was performed using Prism software 
(GraphPad Software). Mean values for each experimental condition 
were calculated.
Patient samples. BM cells from myeloma patients were subjected 
to red blood cell lysis using BD FACS lysing solution (BD Pharmin-
gen). BM myeloma cells were subsequently selected using an EasySep 
Human CD138 Positive Selection Cocktail Kit (Stemcell Tech-
nologies) following the manufacturer’s instructions. Plasma cell 
purity was greater than 90%, as evaluated by FACS analysis using 
anti-CD138–FITC antibody (BD Pharmingen).
Glycolipid extraction, MALDI-TOF mass spectrometry, and tan-
dem mass spectrometry analysis. Glycolipid extraction was performed 
as previously described (42). MS and tandem mass spectrometry 
(MS/MS) data were acquired using a 4800 MALDI-TOF/TOF 
(Applied Biosystems) mass spectrometer. Purified permethylated 
GSLs were dissolved in 10 μl methanol, and 1 μl of dissolved sample 
was premixed with 1 μl of matrix (10 mg/ml 2,5-dihydroxybenzoic 
acid [DHB] in 70% [vol/vol] aqueous methanol), spotted onto a target 
plate (2 × 0.5 μl), and dried under vacuum. The collision energy of the 
MALDI-TOF/TOF was set to 1 kV, and argon was used as a collision 
gas. The 4700 Calibration standard kit, Cal Mix (Applied Biosystems), 
was used as the external calibrant for the MS mode and [Glu1]-Fibrino-
peptide B human (Sigma-Aldrich) was used as an external calibrant for 
the MS/MS mode.
The MS and MS/MS data were processed using Data Explorer 
4.9 Software (Applied Biosystems). The spectra were subjected to 
manual assignment and annotation with the aid of the glycobio-
informatics tool GlycoWorkBench (http://www.glycoworkbench.
org). The proposed assignments for the selected peaks were based 
on 12C isotopic composition together with the known biosynthetic 
pathway. The proposed structures were confirmed by data obtained 
from MS/MS.
Decalcified bone histology. Mouse tibiae were fixed in 4% formal-
dehyde at 4°C. After 24 hours of fixation, tibiae were transferred into 
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